BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Simdax (Levosimendan) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Simdax (Levosimendan)\, from ClinicalTria
 ls.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04020263-601@assetmemo.bio
DTSTAMP:20261121T004032Z
DTSTART;VALUE=DATE:20270203
DTEND;VALUE=DATE:20270204
SUMMARY:Simdax (Levosimendan): Phase 3 readout est. (NCT04020263)
DESCRIPTION:Simdax (Levosimendan)\, phase 3.\nStudy: Effect of Early Use of
  Levosimendan Versus Placebo on Top of a Conventional Strategy of Inotrope
  Use on a Combined Morbidity-mortality Endpoint in Patients With Cardiogen
 ic Shock\nEstimated primary completion: 3 February 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/levosimendan#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT04020263
URL:https://assetmemo.bio/drug/levosimendan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07664748-601@assetmemo.bio
DTSTAMP:20261121T004032Z
DTSTART;VALUE=DATE:20270515
DTEND;VALUE=DATE:20270516
SUMMARY:Simdax (Levosimendan): Phase na readout est. (NCT07664748)
DESCRIPTION:Simdax (Levosimendan)\, phase na\, Heart Failure.\nStudy: Artif
 icial Voice Analysis and Telemonitoring for Heart Failure. A Feasibility S
 tudy\nEstimated primary completion: 15 May 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/levosimendan#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07664748
URL:https://assetmemo.bio/drug/levosimendan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07105202-601@assetmemo.bio
DTSTAMP:20261121T004032Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Simdax (Levosimendan): Phase 4 readout est. (NCT07105202)
DESCRIPTION:Simdax (Levosimendan)\, phase 4.\nStudy: Shorter Weaning From I
 nvasive Ventilation With Levosimendan\nEstimated primary completion: 1 Aug
 ust 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/levosimenda
 n#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 105202
URL:https://assetmemo.bio/drug/levosimendan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07914933-601@assetmemo.bio
DTSTAMP:20261121T004032Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Simdax (Levosimendan): Phase na readout est. (NCT07914933)
DESCRIPTION:Simdax (Levosimendan)\, phase na.\nStudy: The Effect of Levosim
 endan on Pulmonary Artery Pressure and Right Ventricular Function in the P
 erioperative Period in Patients With CTEPH After Pulmonary Thromboendarter
 ectomy\nEstimated primary completion: November 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/levosimendan#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07914933
URL:https://assetmemo.bio/drug/levosimendan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07288398-601@assetmemo.bio
DTSTAMP:20261121T004032Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Simdax (Levosimendan): Phase 3 readout est. (NCT07288398)
DESCRIPTION:Simdax (Levosimendan)\, phase 3\, Pulmonary Hypertension due to
  Left Heart Disease.\nStudy: LEVEL-2: LEVosimendan to Improve Exercise Lim
 itation in Patients With PH-HFpEF-2\nEstimated primary completion: 30 June
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/levosimendan#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07288
 398
URL:https://assetmemo.bio/drug/levosimendan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07436689-601@assetmemo.bio
DTSTAMP:20261121T004032Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Simdax (Levosimendan): Phase 3 readout est. (NCT07436689)
DESCRIPTION:Simdax (Levosimendan)\, phase 3.\nStudy: Long-Term Open-Label E
 xtension Study of Oral Levosimendan\nEstimated primary completion: March 2
 029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/levosimendan#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0743668
 9
URL:https://assetmemo.bio/drug/levosimendan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
